| Literature DB >> 20682457 |
Arthur L Brody1, Edythe D London, Richard E Olmstead, Zoe Allen-Martinez, Stephanie Shulenberger, Matthew R Costello, Anna L Abrams, David Scheibal, Judah Farahi, Steven Shoptaw, Mark A Mandelkern.
Abstract
The aim of this study was to determine whether standard treatments for Tobacco Dependence affect smoking-induced changes in intrasynaptic dopamine (DA) concentration. Forty-three otherwise healthy adult cigarette smokers (10 to 40 cigarettes per day) were treated with either practical group counseling (PGC) psychotherapy (n=14), bupropion HCl (n=14), or matching pill placebo (n=15) (random assignment) for 8 weeks. Before and after treatment, each subject underwent a bolus-plus-continuous-infusion (11)C-raclopride positron emission tomography (PET) scanning session, during which he or she smoked a regular cigarette. The PET scanning outcome measure of interest was percent change in smoking-induced (11)C-raclopride binding potential (BP(ND)) in the ventral caudate/nucleus accumbens (VCD/NAc), as an indirect measure of DA release. Although the entire study sample had a smaller mean smoking-induced reduction in VCD/NAc BP(ND) after treatment (compared to before treatment), this change was highly correlated with smaller total cigarette puff volumes (and not other treatment variables). These data indicate that smoking-induced DA release is dose-dependent, and is not significantly affected by reductions in daily smoking levels or treatment type. Published by Elsevier Ireland Ltd.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20682457 PMCID: PMC2947623 DOI: 10.1016/j.pscychresns.2009.06.004
Source DB: PubMed Journal: Psychiatry Res ISSN: 0165-1781 Impact factor: 3.222